We are live on ! Find out more
TCM

TCG Crossover Management Portfolio holdings

AUM $3.5B
1-Year Est. Return 1,165.83%
This Fund
S&P 500
This Quarter Est. Return
+47.15%
1 Year Est. Return
+1,165.83%
3 Year Est. Return
+3,168.76%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$876M
AUM Growth
+$142M
Cap. Flow
-$21.2M
Cap. Flow %
-2.42%
Top 10 Hldgs %
56.33%
Holding
39
New
2
Increased
1
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$21.1M
2
DYN icon
Dyne Therapeutics
DYN
+$12.3M
3
ELVN icon
Enliven Therapeutics
ELVN
+$9.43M

Top Sells

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$39.2M
2
CMPS
Compass Pathways
CMPS
+$11M
3
SLNO
Soleno Therapeutics
SLNO
+$6.64M
4
KURA icon
Kura Oncology
KURA
+$4.22M
5
THRD
Third Harmonic Bio
THRD
+$2.94M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELVN icon
26
Enliven Therapeutics
ELVN
$3.8B
$9.99M 1.14%
+498,000
New +$9.43M
MBX
27
MBX Biosciences
MBX
$2.99B
$7.42M 0.85%
650,000
– –
NKTR icon
28
Nektar Therapeutics
NKTR
$2.31B
$6.89M 0.79%
266,666
-1
-0% -$11
VTGN icon
29
VistaGen Therapeutics
VTGN
$9.4M
$5.35M 0.61%
2,676,580
– –
KOD icon
30
Kodiak Sciences
KOD
$2.67B
$4.27M 0.49%
1,145,538
– –
KURA icon
31
Kura Oncology
KURA
$964M
$4.24M 0.48%
735,184
-688,458
-48% -$4.22M
TRDA icon
32
Entrada Therapeutics
TRDA
$267M
$3.93M 0.45%
584,955
– –
ADVM
33
DELISTED
Adverum Biotechnologies
ADVM
$3.86M 0.44%
1,796,482
– –
AVTX icon
34
Avalo Therapeutics
AVTX
$1.02B
$2.41M 0.28%
483,000
– –
VTYX
35
DELISTED
Ventyx Biosciences
VTYX
$677K 0.08%
316,195
– –
JBIO
36
Jade Biosciences
JBIO
$1.27B
$640K 0.07%
64,023
– –
CABA icon
37
Cabaletta Bio
CABA
$461M
$132K 0.02%
86,795
– –
CMPS
38
Compass Pathways
CMPS
$1.67B
– –
-3,858,000
Closed -$11M
MLYS icon
39
Mineralys Therapeutics
MLYS
$2.39B
– –
-2,470,265
Closed -$39.2M
1
2

Similar funds

DILIC
Dai-ichi Life Insurance Company Tokyo, Japan $3.49B AUM 27.28% 1-Year Est. Return
IIM
Intact Investment Management Montreal, Quebec, Canada $3.51B AUM 39.24% 1-Year Est. Return
KCM
Kedalion Capital Management London, United Kingdom $3.48B AUM 17.74% 1-Year Est. Return
ACM
Aquatic Capital Management Chicago, Illinois $3.48B AUM 24.9% 1-Year Est. Return
BCP
BDT Capital Partners Chicago, Illinois $3.51B AUM 31.02% 1-Year Est. Return
AL
Aspiriant LLC Los Angeles, California $3.51B AUM 13.98% 1-Year Est. Return
ACA
Anchor Capital Advisors Boston, Massachusetts $3.51B AUM 16.99% 1-Year Est. Return
MSC
MUFG Securities (Canada) New York $3.48B AUM 45.13% 1-Year Est. Return

TCG Crossover Management's Q2 2025 Portfolio in Review

As of Q2 2025, TCG Crossover Management held 39 positions worth $876M, up 19% from $733M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

TCG Crossover Management's Q2 2025 filing shows 2 new, 1 increased, 4 reduced and 2 closed positions. Its largest new stake was Agios Pharmaceuticals: 697,003 shares worth $23.2M. The largest sale was Mineralys Therapeutics, an estimated $39.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TCG Crossover Management's largest Q2 2025 buy was Agios Pharmaceuticals: 697,003 shares worth $23.2M.
  • TCG Crossover Management added most to Dyne Therapeutics in Q2 2025, an estimated $12.3M increase.
  • TCG Crossover Management's biggest Q2 2025 reduction was Soleno Therapeutics, cutting an estimated $6.64M.
  • TCG Crossover Management fully exited Mineralys Therapeutics in Q2 2025, selling an estimated $39.2M.
  • TCG Crossover Management's ten largest holdings make up 56% of its $876M portfolio in Q2 2025.
  • TCG Crossover Management opened 2 new positions and closed 2 in Q2 2025.
  • TCG Crossover Management's portfolio value rose 19% quarter-over-quarter to $876M.

Based on TCG Crossover Management's 13F filing for Q2 2025, filed 14 Aug 2025.